Lipid-lowering drugs — HMG-CoA reductase inhibitor
Description of the active substance (INN)
1. The primary hypercholesterolemia (heterozygous familial and non-family hypercholesterolemia, according to Fredrickson Type IIa of), combined (mixed) hyperlipidemia (by Frederickson types IIb and III of), familial endogenous hypertriglyceridemia (by Frederickson type IV), resistant to dietary treatments.
2. Homozygous Familial Hypercholesterolemia (as a supplement to the lipid-lowering therapy, including autologous transfusion purified from the blood LDL).
3. Diseases of the CAS against the background of dyslipidemia, secondary prevention to reduce the overall risk of death, myocardial infarction and rehospitalization for angina.
From the nervous system: often 2% — insomnia, dizziness; less than 2% — headache, asthenia, malaise, drowsiness, abnormal dreams, amnesia, peripheral neuropathy, amnesia, emotional lability, ataxia, paralysis of the facial nerve, hyperkinesis, depression, hypersensitivity, loss of consciousness.
From the senses: less than 2% — amblyopia, tinnitus, dryness of the conjunctiva, disturbance of accommodation, eye hemorrhage, deafness, glaucoma, parosmiya, loss of taste, taste perversion.
From the CCC: usually 2% — pain in the chest; less than 2% — palpitation, vasodilatation, migraine, postural hypotension, increased blood pressure, phlebitis, arrhythmia, angina pectoris.
From hemopoiesis system: less than 2% — anemia, lymphadenopathy, thrombocytopenia.
The respiratory system: often 2% — bronchitis, rhinitis; less than 2% — pneumonia, dyspnea, asthma, epistaxis.
From the digestive system: often 2% — nausea; less than 2% — heartburn, constipation or diarrhea, flatulence, abdominal pain, anorexia, decreased or increased appetite, dry mouth, regurgitation, dysphagia, vomiting, stomatitis, esophagitis, glossitis, erosive and ulcerative lesions of the oral mucosa, gastroenteritis, hepatitis, biliary colic, cheilitis, ulcer 12 duodenal ulcer, pancreatitis, cholestatic jaundice, abnormal liver function, rectal bleeding, melena, bleeding gums, tenesmus.
From the musculoskeletal system: often 2% — arthritis; less than 2% — spasms of the leg muscles, bursitis, tenosynovitis, myositis, myopathy, arthralgia, myalgia, rhabdomyolysis, torticollis, muscular hypertonicity, contracture of joints.
With the genitourinary system: often 2% — urogenital infections, peripheral edema; less than 2% — dysuria (including pollakiuria, nocturia, urinary incontinence or urinary retention, compelling urge to urinate), nephritis, hematuria, vaginal bleeding, epididymitis, decreased libido, impotence, abnormal ejaculation.
For the skin: often 2% — alopecia, increased sweating, eczema, seborrhea, ecchymosis, petechiae.
Allergic reaction: less than 2% — itchy skin, skin rash, contact dermatitis, rare — urticaria, angioneurotic edema, facial edema, photosensitivity, anaphylaxis, erythema multiforme exudative (including Stevens-Johnson syndrome), toxic epidermal necrolysis (syndrome Lyell).
Laboratory findings: less than 2% — hyperglycemia, hypoglycemia, increased serum CPK, albuminuria.
Others: less than 2% — weight gain, gynecomastia, mammalgia, exacerbation of gout.
Hypersensitivity, active liver disease (including chronic active hepatitis, chronic alcoholic hepatitis), increased activity of «liver» transaminases (more than 3 times) of unknown origin, hepatic failure (severity A and B on the scale of Child-Pyuga), pregnancy, lactation. Severe electrolyte disturbances, endocrine and metabolic disorders, alcoholism, liver disease, a history of hypotension, severe acute infections, uncontrollable seizures, extensive surgery, trauma, children’s age (efficacy and safety have not been established).